Tana Mongeau calls out cheating ex in scandalous YouTube video: 'Embarrassing and disgusting'

GlobeNewswireKim Stratton, CEO, resigns from OrphazymeOrphazyme A/S Company announcement                                                                                         No. 72/2020 Inside information Company Registration No. 32266355 Copenhagen, Denmark, December 10, 2020 – Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton has decided to resign from Orphazyme following a dialogue initiated by the board of directors. Orphazyme will initiate a search for a new CEO immediately. Meanwhile, in order to ensure continuity going forward, Georges Gemayel, Chairman of the Board of Directors, will temporarily assist the executive team of Orphazyme with the day-to-day operations until a new CEO is appointed.Chairman of the Board of Directors, George Gemayel, states that “We are fortunate that Kim Stratton was available at a critical juncture of Orphazyme’s history during which the company successfully raised new equity of approximately DKK 1.3 bn, completed a listing of ADS in the Unites States and filed an NDA with the FDA and an MAA with the EMA. With these important milestones and the establishment of our operations in the United States, Orphazyme is well-positioned for a potential commercial launch of our product candidate, arimoclomol in the Unites States and Europe. Until…
Read More